A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect o

Trial Details

NCT ID
NCT06228326
Phase
PHASE1 / PHASE2
Sponsor
Krystal Biotech, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • KB707
  • Pembrolizumab (KEYTRUDA®)
  • Chemotherapy
  • Docetaxel
Locations (sample)
  • Dothan, Alabama, United States|31.22323,-85.39049
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Redlands, California, United States|34.05557,-117.18254
  • Weston, Florida, United States|26.10037,-80.39977

Key Eligibility Criteria

  • Age 18 years or older at the time of informed consent
  • Life expectancy \>12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Have at least one measurable lung lesion per RECIST v1.1 at Screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →